14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $24.22 $29.21 Friday, 3rd May 2024 PTGX stock ended at $26.09. This is 2.15% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 3.17% from a day low at $25.75 to a day high of $26.56.
90 days $24.22 $33.34
52 weeks $13.72 $33.34

Historical Protagonist Therapeutics Inc prices

Date Open High Low Close Volume
May 03, 2024 $26.20 $26.56 $25.75 $26.09 355 455
May 02, 2024 $25.74 $25.97 $25.28 $25.54 451 164
May 01, 2024 $25.18 $26.32 $24.78 $25.56 697 386
Apr 30, 2024 $25.25 $25.50 $24.91 $25.11 352 958
Apr 29, 2024 $25.43 $25.83 $25.13 $25.56 406 232
Apr 26, 2024 $24.61 $25.23 $24.22 $25.15 357 577
Apr 25, 2024 $25.13 $25.14 $24.52 $24.66 503 143
Apr 24, 2024 $26.92 $27.61 $25.62 $25.70 326 417
Apr 23, 2024 $26.65 $27.78 $26.61 $26.85 325 247
Apr 22, 2024 $25.84 $26.99 $25.72 $26.61 295 996
Apr 19, 2024 $25.11 $25.63 $24.79 $25.61 430 716
Apr 18, 2024 $25.34 $25.76 $25.17 $25.22 365 868
Apr 17, 2024 $26.39 $26.39 $25.35 $25.57 517 234
Apr 16, 2024 $26.30 $26.40 $25.94 $26.11 436 198
Apr 15, 2024 $27.18 $27.29 $26.32 $26.58 425 863
Apr 12, 2024 $27.52 $27.57 $26.66 $27.04 568 315
Apr 11, 2024 $28.20 $28.40 $27.40 $27.66 511 324
Apr 10, 2024 $28.22 $28.54 $27.74 $27.88 689 369
Apr 09, 2024 $28.15 $29.21 $27.97 $29.13 885 903
Apr 08, 2024 $28.06 $28.11 $27.43 $28.09 295 922
Apr 05, 2024 $27.45 $28.61 $26.92 $28.00 381 765
Apr 04, 2024 $28.42 $29.00 $27.55 $27.65 776 842
Apr 03, 2024 $27.71 $28.40 $27.71 $28.07 516 116
Apr 02, 2024 $27.74 $28.11 $27.59 $27.99 731 773
Apr 01, 2024 $28.77 $28.90 $27.64 $28.28 594 761
Click to get the best stock tips daily for free!

About Protagonist Therapeutics Inc

Protagonist Therapeutics Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorder... PTGX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT